{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:27:14Z","timestamp":1791358034537,"version":"4.3.1"},"reference-count":86,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Although immune checkpoint inhibitors (ICIs) have provided practice-changing outcomes in treating many cancers, ICI-related gastrointestinal toxicity can limit their use. Upper gastrointestinal toxicity is not common nor as well described as lower gastrointestinal toxicity. We aimed to characterize the clinical presentation, endoscopic and histologic features, treatment response, and outcomes of ICI-related esophagitis. <jats:bold>Methods:<\/jats:bold> We retrospectively studied patients at The University of Texas MD Anderson Cancer Center in whom esophagitis developed after receiving ICIs from June 2011 through January 2020. We included patients with endoscopic evidence of esophagitis and excluded those with other obvious causes of esophagitis. A chi-square test was used to assess associations between categorical variables. The Mann-Whitney U test was used to compare differences between continuous variables. <jats:bold>Results:<\/jats:bold> Of 657 consecutive patients who underwent esophagogastroduodenoscopy (EGD) during or within 6 months of completing ICI-based therapy, 21 (3%) had esophagitis deemed to be from ICIs. Of these patients, 1 (5%) received an inhibitor of CTLA-4 alone, 15 (71%) received anti\u2013PD-1 or PD-L1 monotherapy, and 5 (24%) received a combination of these. Median time from ICI initiation to onset of esophagitis was 4 months. Upon evaluation with EGD, only 3 patients (14%) had isolated esophageal involvement; 18 (86%) had concurrent involvement of the stomach, duodenum, or both. Most patients (67%) were treated with proton pump inhibitors, and 4 (19%) received steroids (prednisone or budesonide). The mortality rate was 38% (median follow-up, 15 months). <jats:bold>Conclusions:<\/jats:bold> Esophagitis associated with ICI use is rare. The diagnosis is one of exclusion because its clinical presentation appears similar to that of inflammation resulting from other causes. It often occurs in conjunction with other upper gastrointestinal toxicity. Symptoms are mild and respond well to nonimmunosuppressive treatment, with few severe complications.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7675","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T16:01:54Z","timestamp":1629475314000},"page":"896-904","source":"Crossref","is-referenced-by-count":35,"title":["Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor\u2013Related Esophagitis"],"prefix":"10.6004","volume":"19","author":[{"given":"Kavea","family":"Panneerselvam","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Baylor College of Medicine, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan N.","family":"Amin","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongguang","family":"Wei","sequence":"additional","affiliation":[{"name":"3Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Tan","sequence":"additional","affiliation":[{"name":"3Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip J.","family":"Lum","sequence":"additional","affiliation":[{"name":"4Department of Gastroenterology, Hepatology, and Nutrition, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Gastroenterology, Hepatology, and Nutrition, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Richards","sequence":"additional","affiliation":[{"name":"4Department of Gastroenterology, Hepatology, and Nutrition, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Altan","sequence":"additional","affiliation":[{"name":"5Department of Thoracic\/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"4Department of Gastroenterology, Hepatology, and Nutrition, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Gastroenterology, Hepatology, and Nutrition, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref561","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/jco.2015.33.15_suppl.9004","article-title":"Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study [abstract]","volume":"33","author":"Hodi","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter","year":"2018","journal-title":"Gastroenterology"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/jco.2015.33.15_suppl.9004","article-title":"Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study [abstract]","volume":"33","author":"Hodi","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"9566","DOI":"10.1200\/JCO.2017.35.15_suppl.9566","article-title":"Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1\/CTLA-4 inhibitors (COMBO) in melanoma [abstract]","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejca.2017.07.029","article-title":"Nivolumab-associated nausea and vomiting as an immune adverse event","volume":"84","author":"Shi","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14309\/ajg.0000000000000324","article-title":"Esophagitis in non-small cell lung carcinoma treatment caused by pembrolizumab","volume":"115","author":"Yoshida","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref371","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy [published online April 27, 2020]","author":"Patil","journal-title":"Arch Pathol Lab Med"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2020.01.008","article-title":"Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study","volume":"141","author":"Niho","year":"2020","journal-title":"Lung Cancer"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref801","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy [published online April 27, 2020]","author":"Patil","journal-title":"Arch Pathol Lab Med"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejca.2017.07.029","article-title":"Nivolumab-associated nausea and vomiting as an immune adverse event","volume":"84","author":"Shi","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe esophagitis and gastritis from nivolumab therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep J"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00000478-198412000-00002","article-title":"Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis","volume":"8","author":"Brown","year":"1984","journal-title":"Am J Surg Pathol"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter","year":"2018","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"9566","DOI":"10.1200\/JCO.2017.35.15_suppl.9566","article-title":"Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1\/CTLA-4 inhibitors (COMBO) in melanoma [abstract]","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"e00334","DOI":"10.1002\/rcr2.334","article-title":"Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient","volume":"6","author":"Onuki","year":"2018","journal-title":"Respirol Case Rep"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000491862","article-title":"Severe gastritis after administration of nivolumab and ipilimumab","volume":"11","author":"Nishimura","year":"2018","journal-title":"Case Rep Oncol"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment of malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13014-020-01518-2","article-title":"A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and\/or M1 lymph node metastasis or locoregional recurrence","volume":"15","author":"Liu","year":"2020","journal-title":"Radiat Oncol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1975.tb00291.x","article-title":"Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics","volume":"14","author":"Brincker","year":"1975","journal-title":"Scand J Haematol"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic gastritis after nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment of malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic gastritis after nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe esophagitis and gastritis from nivolumab therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep J"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2020.01.008","article-title":"Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study","volume":"141","author":"Niho","year":"2020","journal-title":"Lung Cancer"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u2018immunomodulatory gastroenterocolitis\u2019","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000491862","article-title":"Severe gastritis after administration of nivolumab and ipilimumab","volume":"11","author":"Nishimura","year":"2018","journal-title":"Case Rep Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00000478-198412000-00002","article-title":"Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis","volume":"8","author":"Brown","year":"1984","journal-title":"Am J Surg Pathol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"e00334","DOI":"10.1002\/rcr2.334","article-title":"Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient","volume":"6","author":"Onuki","year":"2018","journal-title":"Respirol Case Rep"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"13","DOI":"10.14309\/ajg.0000000000000324","article-title":"Esophagitis in non-small cell lung carcinoma treatment caused by pembrolizumab","volume":"115","author":"Yoshida","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13014-020-01518-2","article-title":"A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and\/or M1 lymph node metastasis or locoregional recurrence","volume":"15","author":"Liu","year":"2020","journal-title":"Radiat Oncol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.1975.tb00291.x","article-title":"Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics","volume":"14","author":"Brincker","year":"1975","journal-title":"Scand J Haematol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u2018immunomodulatory gastroenterocolitis\u2019","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/8\/article-p896.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/19\/8\/article-p896.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T18:49:21Z","timestamp":1636742961000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/8\/article-p896.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":86,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7675","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}